These positive Phase 3 induction results for tulisokibart are the first for an anti-TL1A biologic. They represent an important step forward for patients with moderately to severely active ulcerative ...
The world’s first CAR-T therapy for solid tumors has passed muster in China, with the country's National Medical Products ...
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026Detailed Phase 1b Data Expected to be Presented at a Major ...
CARSgen Therapeutics has claimed approval in China, its home market, for satricabtagene autoleucel (satri-cel), said to be ...
ABL Bio announced on June 17 that Givastomig (ABL111), a bispecific antibody immuno-oncology therapy co-developed with the ...
SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced ...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration ...
ABL Bio said Wednesday that the US Food and Drug Administration granted Fast Track designation to Givastomig (ABL111), its ...
The global postbiotic supplements market is entering a period of accelerated growth as consumers, healthcare providers, and ...
Think willpower is the only way to maintain weight loss? Think again. A new study reveals how a specific gut bacteria ...
Nectin Therapeutics, a clinical-stage oncology company developing first-in-class immuno-oncology and antibody-drug conjugate (ADC) therapies, today announced the presentation of Phase 1a/1b clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results